Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.43 |
| ▸ | MGLL | Q99685 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13246575 | 0.84 | FAAH (0.45) | FAAHMGLL | |
| SCHEMBL3023940 | 0.80 | MGLL (0.40) | FAAHMGLLSMN1; SMN2RAB9AHPGD | |
| SCHEMBL13246570 | 0.79 | MGLL (0.65) | FAAHMGLLSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5640188 | 0.78 | MGLL (0.49) | FAAHMGLLSMN1; SMN2RAB9AHPGD | |
| SCHEMBL5644769 | 0.75 | MGLL (0.49) | FAAHMGLLSMN1; SMN2RAB9AHPGD | |
| SCHEMBL3026137 | 0.75 | HPGD (0.48) | FAAHMGLLSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL5641596 | 0.74 | FAAH (0.67) | FAAHMGLL | |
| SCHEMBL5642585 | 0.72 | FAAH (0.48) | FAAHMGLLSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5641990 | 0.72 | FAAH (0.47) | FAAHMGLLSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3014204 | 0.71 | MGLL (0.48) | FAAHMGLLSMN1; SMN2RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2010-07-29 | — | — | US | disclosed |
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2010-07-29 | — | — | US | disclosed |
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2010-07-29 | — | — | US | disclosed |
| US-7718669-B2 | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718669-B2 | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718669-B2 | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | SANOFI-AVENTIS (FR) | 2010-05-18 | — | — | US | disclosed |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI-AVENTIS (FR) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190801-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LIPC, LPL | FAAH 150/4885MGLL 5/4885SMN1; SMN2 4402/4885 |
| US-20090030011-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | PNLIP, LIPC, LPL | FAAH 150/4885MGLL 5/4885SMN1; SMN2 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.